Can your doctor and stroke hospital rub two neurons together and deduce that this could be an effective way to deliver BDNF? BDNF is very useful in our recovery. Does your doctor know that and doing ANYTHING AT ALL about it? Or intranasal delivery?
Yes, this is in mice and for Parkinsons but do they have the ability to think outside the failed box of stroke recovery? Ask, and not politely, how they are going to get you 100% recovered. Anything less is complete failure on their part and the board of directors should have a policy to replace those failures. I take no prisoners.
- BDNF (137)
- nasal delivery (3)
- 13 nasal delivery options (5)
Focused ultrasound enhanced intranasal delivery of brain derived neurotrophic factor produces neurorestorative effects in a Parkinson's disease mouse model
Ji R1, Smith M1, Niimi Y1, Karakatsani ME1, Murillo MF1, Jackson-Lewis V2,3,4, Przedborski S2,5,3,4, Konofagou EE6,7.
Author information
- 1
- Department of Biomedical Engineering, Columbia University, New York, New York, USA.
- 2
- Department of Pathology & Cell Biology, Columbia University, New York, New York, USA.
- 3
- Department of the Center for Motor Neuron Biology and Disease, Columbia University, New York, New York, USA.
- 4
- Department of the Columbia Translational Neuroscience Initiative, Columbia University, New York, New York, USA.
- 5
- Department of Neurology, Columbia University, New York, New York, USA.
- 6
- Department of Biomedical Engineering, Columbia University, New York, New York, USA. ek2191@columbia.edu.
- 7
- Department of Radiology, Columbia University, New York, New York, USA. ek2191@columbia.edu.
Abstract
Focused
ultrasound-enhanced intranasal (IN + FUS) delivery is a noninvasive
approach that utilizes the olfactory pathway to administer
pharmacological agents directly to the brain, allowing for a more
homogenous distribution in targeted locations compared to IN delivery
alone. However, whether such a strategy has therapeutic values,
especially in neurodegenerative disorders such as Parkinson's disease
(PD), remains to be established. Herein, we evaluated whether the
expression of tyrosine hydroxylase (TH), the rate limiting enzyme in
dopamine catalysis, could be enhanced by IN + FUS delivery of
brain-derived neurotrophic factor (BDNF) in a toxin-based PD mouse
model. Mice were put on the subacute dosing regimen of
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), producing bilateral
degeneration of the nigrostriatal pathway consistent with early-stage
PD. MPTP mice then received BDNF intranasally followed by multiple
unilateral FUS-induced blood-brain barrier (BBB) openings in the left
basal ganglia for three consecutive weeks. Subsequently, mice were
survived for two months and were evaluated morphologically and
behaviorally to determine the integrity of their nigrostriatal
dopaminergic pathways. Mice receiving IN + FUS had significantly
increased TH immunoreactivity in the treated hemisphere compared to the
untreated hemisphere while mice receiving only FUS-induced BBB opening
or no treatment at all did not show any differences. Additionally,
behavioral changes were only observed in the IN + FUS treated mice,
indicating improved motor control function in the treated hemisphere.
These findings demonstrate the robustness of the method and potential of
IN + FUS for the delivery of bioactive factors for treatment of
neurodegenerative disorder.
- PMID:
- 31852909
- PMCID:
- PMC6920380
- DOI:
- 10.1038/s41598-019-55294-5
No comments:
Post a Comment